Close

Drug Research

ST Pharm and Quantoom Partner to Enhance RNA Manufacturing Flexibility

ST Pharm and Quantoom Biosciences have announced an extended collaboration to advance the development and manufacturing of RNA-based vaccines and therapeutics. This partnership integrates...

Bridge Biotherapeutics and HitGen Initiate Research Collaboration to Advance Novel Cancer Therapeutics Program

Bridge Biotherapeutics, a clinical-stage biotech company, announced that it has entered into a joint research agreement with HitGen Inc., a Chinese drug discovery platform...

Novartis and Versant Ventures Launch Borealis Biosciences with $150M Investment

Novartis and Versant Ventures have launched Borealis Biosciences with a substantial $150 million Series A funding. The new biotech firm aims to develop next-generation...

Bridge Biotherapeutics and HitGen Initiate Research Collaboration to Advance Novel Cancer Therapeutics Program

Bridge Biotherapeutics, a clinical-stage biotech company announced that it has entered into a joint research agreement with HitGen Inc., a Chinese drug discovery platform...

FUJIFILM Diosynth Biotechnologies Celebrates Opening of Billingham, UK Microbial Manufacturing Facility

FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, advanced therapies, and oncolytic viruses hosted a celebration for...

Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic

Hoth Therapeutics, Inc., a patient-focused biopharmaceutical company, announced that it has entered into a Master Services Agreement with Aronnax, Inc. for its HT-KIT cancer...

Tonix advances development of TNX-801 to prevent mpox infection

Tonix Pharmaceuticals Holding Corp., a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, has reiterated its commitment to advance development...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read